VRDN 006
Alternative Names: VRDN-006Latest Information Update: 02 Jul 2024
Price :
$50 *
At a glance
- Originator Viridian Therapeutics
- Class Immunoglobulin Fc fragments; Monoclonal antibodies
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 02 Jul 2024 Viridian Therapeutics plans a phase I trial in healthy volunteers in early 2025 (SC)
- 30 Oct 2023 Viridian plans to file an IND application for Autoimmune disorders by year end 2024
- 30 Oct 2023 Pharmacodynamics and adverse events data from preclinical studies in Autoimmune disorders released by Viridian Therapeutics